JP2024512069A - ゾルミトリプタンを含む医薬組成物 - Google Patents

ゾルミトリプタンを含む医薬組成物 Download PDF

Info

Publication number
JP2024512069A
JP2024512069A JP2023558740A JP2023558740A JP2024512069A JP 2024512069 A JP2024512069 A JP 2024512069A JP 2023558740 A JP2023558740 A JP 2023558740A JP 2023558740 A JP2023558740 A JP 2023558740A JP 2024512069 A JP2024512069 A JP 2024512069A
Authority
JP
Japan
Prior art keywords
composition
zolmitriptan
hours
points
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512069A5 (enExample
Inventor
ウッド，マイケル
リリー，ジェームズ
Original Assignee
マップライト セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マップライト セラピューティクス，インコーポレイテッド filed Critical マップライト セラピューティクス，インコーポレイテッド
Publication of JP2024512069A publication Critical patent/JP2024512069A/ja
Publication of JP2024512069A5 publication Critical patent/JP2024512069A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023558740A 2021-03-25 2022-03-24 ゾルミトリプタンを含む医薬組成物 Pending JP2024512069A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163165938P 2021-03-25 2021-03-25
US63/165,938 2021-03-25
US202263306377P 2022-02-03 2022-02-03
US63/306,377 2022-02-03
PCT/US2022/021738 WO2022204399A1 (en) 2021-03-25 2022-03-24 Pharmaceutical compositions comprising zolmitriptan

Publications (2)

Publication Number Publication Date
JP2024512069A true JP2024512069A (ja) 2024-03-18
JP2024512069A5 JP2024512069A5 (enExample) 2025-04-16

Family

ID=83397893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558740A Pending JP2024512069A (ja) 2021-03-25 2022-03-24 ゾルミトリプタンを含む医薬組成物

Country Status (10)

Country Link
US (1) US20240189240A1 (enExample)
EP (1) EP4313037A4 (enExample)
JP (1) JP2024512069A (enExample)
KR (1) KR20240004330A (enExample)
AU (1) AU2022246101A1 (enExample)
BR (1) BR112023019407A2 (enExample)
CA (1) CA3213383A1 (enExample)
IL (1) IL307194A (enExample)
MX (1) MX2023011240A (enExample)
WO (1) WO2022204399A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117017983B (zh) * 2023-10-09 2023-12-22 中山大学 曲普坦类药物在制备抗感染药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045913A1 (en) * 2004-09-01 2006-03-02 Stankov Bojidar Mihaylov Controlled-release formulations containing tryptophan or its metabolites
JP2015514727A (ja) * 2012-04-18 2015-05-21 コンテラ ファーマ アンパルトセルスカブＣｏｎｔｅｒａ Ｐｈａｒｍａ Ａｐｓ 運動障害の管理の改善に適した経口投与可能な医薬製剤
WO2019245925A1 (en) * 2018-06-19 2019-12-26 National University Of Singapore Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240022B1 (en) * 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
US20100179202A1 (en) * 2009-01-14 2010-07-15 Ajanta Pharma Limited. Orally disintegrating composition of zolmitriptan
MX2016010213A (es) * 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
DK3261640T3 (da) * 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
CA3158781A1 (en) * 2019-10-23 2021-04-29 Michael Wood Methods of treating the symptoms of autism spectrum disorder

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045913A1 (en) * 2004-09-01 2006-03-02 Stankov Bojidar Mihaylov Controlled-release formulations containing tryptophan or its metabolites
JP2015514727A (ja) * 2012-04-18 2015-05-21 コンテラ ファーマ アンパルトセルスカブＣｏｎｔｅｒａ Ｐｈａｒｍａ Ａｐｓ 運動障害の管理の改善に適した経口投与可能な医薬製剤
WO2019245925A1 (en) * 2018-06-19 2019-12-26 National University Of Singapore Formulations of 5-hydroxy tryptophan (5-htp) for better bioavailability for various indications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PSYCHOPHARMACOLOGY, vol. 157:131-141, JPN6026018386, 2001, ISSN: 0005853654 *

Also Published As

Publication number Publication date
US20240189240A1 (en) 2024-06-13
AU2022246101A1 (en) 2023-10-12
EP4313037A1 (en) 2024-02-07
CA3213383A1 (en) 2022-09-29
WO2022204399A1 (en) 2022-09-29
IL307194A (en) 2023-11-01
MX2023011240A (es) 2024-01-12
KR20240004330A (ko) 2024-01-11
EP4313037A4 (en) 2025-02-26
BR112023019407A2 (pt) 2023-11-28

Similar Documents

Publication Publication Date Title
JP5968300B2 (ja) 高用量、水溶性及び吸湿性薬剤基質用の制御放出性剤形
TWI241188B (en) Sertraline salts and sustained-release dosage forms of sertraline
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
JP4744142B2 (ja) ラモトリギンを含む徐放性処方
JP7402911B2 (ja) 自己調節性の浸透性胃保持性薬物送達システム
US7569612B1 (en) Methods of use of fenofibric acid
RU2298402C2 (ru) Твердая лекарственная форма тербинафина для перорального введения
US20160081985A1 (en) Cenicriviroc compositions and methods of making and using the same
CA2745741A1 (en) Zaleplon gastroretentive drug delivery system
JP2007509155A (ja) クエチアピンを含有する薬剤
EA035837B1 (ru) Лекарственное средство для профилактики или лечения заболевания центральной нервной системы, а также способы его получения и применения
KR102486126B1 (ko) 알펠리십을 포함하는 제약 조성물
CA2606740A1 (en) Quinine-containing controlled-release formulations
AU2012326976B2 (en) Sustained-release preparation
RU2435573C2 (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
JP2008517970A (ja) 不眠症の治療用薬剤の遅動型投与形態
JPWO2014171542A1 (ja) 放出制御製剤
US20240189240A1 (en) Pharmaceutical compositions comprising zolmitriptan
US20210077416A1 (en) Compositions for Treatment of Attention Deficit Hyperactivity Disorder
US20070134322A1 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
CN117750957A (zh) 包含佐米曲坦的药物组合物
EP2298290A1 (en) Controlled release composition comprising levetiracetam
JP4866170B2 (ja) 睡眠薬の放出制御医薬組成物及びその製造方法
WO2019018158A1 (en) PHARMACEUTICAL COMPOSITIONS
CN117279638A (zh) 包含吡斯的明的延长释放组合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260804